Monday, August 05, 2019 7:33:05 PM
survivor1x,
That's what should be determined. I don't agree with the way the approval was given, especially for use by all patients which is where I agree completely with flipper44. The approval was given based on very questionable data and the whole process should be investigated from the top down with treatment stopped for those not willing or able to comply with usage directives. In the mean time every patient, doctor and insurance provider should be made immediately aware of the questions with regard to the data to put pressure on FDA to make full unedited data disclosure available.
The elephant in the room seems pretty unresponsive. Getting this and many other messes it represents, as disclosed on this board and elsewhere, cleaned up by patient advocate groups with attorneys and smaller media groups that actually care to organize an awareness campaign might be a good first step. Best wishes.
That's what should be determined. I don't agree with the way the approval was given, especially for use by all patients which is where I agree completely with flipper44. The approval was given based on very questionable data and the whole process should be investigated from the top down with treatment stopped for those not willing or able to comply with usage directives. In the mean time every patient, doctor and insurance provider should be made immediately aware of the questions with regard to the data to put pressure on FDA to make full unedited data disclosure available.
The elephant in the room seems pretty unresponsive. Getting this and many other messes it represents, as disclosed on this board and elsewhere, cleaned up by patient advocate groups with attorneys and smaller media groups that actually care to organize an awareness campaign might be a good first step. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
